Advertisement

Current Dermatology Reports

, Volume 8, Issue 1, pp 14–25 | Cite as

Nanotechnology for Psoriasis Therapy

  • Emily C. Murphy
  • Samuel W. Schaffter
  • Adam J. FriedmanEmail author
Psoriasis (J Wu, Section Editor)
  • 19 Downloads
Part of the following topical collections:
  1. Topical Collection on Psoriasis

Abstract

Purpose of Review

To summarize the use of nanotechnology-based drug delivery systems for psoriasis therapies, focusing on recent studies of treatment efficacy in humans and murine models.

Recent Findings

Both topical and oral psoriasis medications, in addition to alternative psoriasis therapies and siRNAs targeting genes involved in the pathogenesis of psoriasis, have been incorporated into nanocarriers. Numerous studies demonstrate that nanocarriers can enhance the efficacy and reduce side effects of their included drugs through increased skin retention, sustained release, and decreased systemic absorption. However, the number of studies in humans is limited and while the short-term use of nanocarriers appears safe, long-term outcomes are unknown. Additionally, few studies compare different types of nanocarriers, making it difficult to recommend which types of nanocarriers are the best.

Summary

While recent research has demonstrated the benefit of nanotechnology-based drug delivery systems for psoriasis, more research, especially in humans, is needed to optimize drug-loaded nanocarriers for clinical use.

Keywords

Psoriasis Nanotechnology Transdermal drug delivery Nanomedicine Nanocarriers 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors of this paper have no conflicts of interest to declare.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Parisi R, Symmons DP, CEM G, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2012;133:377.PubMedGoogle Scholar
  2. 2.
    Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–59.PubMedGoogle Scholar
  3. 3.
    Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62:114–35.PubMedGoogle Scholar
  4. 4.
    Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18:E2297.  https://doi.org/10.3390/ijms18112297.CrossRefPubMedGoogle Scholar
  5. 5.
    Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451–85.PubMedGoogle Scholar
  6. 6.
    David Schairer MD, Jason Chouake MD, Adnan Nasir MD, Adam Friedman MD, Jason Chouake MD, Adnan Nasir MD, et al. Nanotechnology applications in dermatology. Clin Nanomed Handb. 2013;89(1):126–36.  https://doi.org/10.1201/b15642-6.CrossRefGoogle Scholar
  7. 7.
    Garg. Nanotechnological approaches for the effective management of psoriasis. Artif Cells Nanomed Biotechnol. 2016;44:1374–82.PubMedGoogle Scholar
  8. 8.
    Rahman. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy. Expert Opin Drug Deliv. 2015;12:635–52.PubMedGoogle Scholar
  9. 9.
    Wan T, Pan W, Long Y, Yu K, Liu S, Ruan W, et al. Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities. Int J Nanomed. 2017;12:1485–97.Google Scholar
  10. 10.
    Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3:16–20.PubMedGoogle Scholar
  11. 11.
    de Leeuw J, de Vijlder HC, Bjerring P, Neumann H a M. Liposomes in dermatology today. J Eur Acad Dermatol Venereol. 2009;23:505–16.PubMedGoogle Scholar
  12. 12.
    • Raza K, Singh B, Lohan S, Sharma G, Negi P, Yachha Y, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm. 2013;456:65–72 Compared skin retention and anti-psoriatic efficacy of tretinoin-loaded liposomes, ethosomes, solid lipid nanoparticles, and nanostructured lipid carriers in a murine model. This is one of the few studies comparing carriers against each other rather than to marketed products. The liposomes and nanostructured lipid carriers led to the highest tretinoin skin retention and efficacy.PubMedGoogle Scholar
  13. 13.
    •• Abdelgawad R, Maha N, Mofta N, Hamza M. Phospholipid membrane tubulation using ceramide doping “cerosomes”: characterization and clinical application in psoriasis treatment. Eur J Pharm Sci : official journal of the European Federation for Pharmaceutical Sciences. 2017;101:258–68 Vesicular carriers including both tazarotene and ceramide improved psoriasis symptoms more than both commercial tazarotene gel and tazarotene-loaded vesicular carriers without ceramides in a randomized, controlled trial with 20 patients. This is one of the few trials with human participants. Google Scholar
  14. 14.
    •• Kumar R, Dogra S, Amarji B, Singh B, Kumar S, null S, et al. Efficacy of novel topical liposomal formulation of cyclosporine in mild to moderate stable plaque psoriasis: a randomized clinical trial. JAMA Dermatol. 2016;152:807–15 Cyclosporine-loaded liposomes were used to treat 38 patients in this double-blind, randomized controlled trial. Cyclosporine-liposomes resulted in higher plaque clearance than a commercial cyclosporine cream but lower clearance than clobetasol propionate. No systemic cyclosporine absorption was detected with blood sampling in patients treated with cyclosporine-liposomes. PubMedGoogle Scholar
  15. 15.
    Doppalapudi S, Jain A, Chopra DK, Khan W. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis. Eur J Pharm Sci. 2017;96:515–29.PubMedGoogle Scholar
  16. 16.
    Anderson M, Omri A. The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Delivery. 2004;11:33–9.PubMedGoogle Scholar
  17. 17.
    Zhang Y-T, Shen L-N, Zhao J-H, Feng N-P. Evaluation of psoralen ethosomes for topical delivery in rats by using in vivo microdialysis. Int J Nanomedicine. 2014;9:669–78.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Patel R, Singh SK, Singh S, Sheth N, Gendle R. Development and Characterization of Curcumin Loaded Transfersome for Transdermal Delivery. J Pharm Sci Res. 2009;1(4):71–80.Google Scholar
  19. 19.
    Abdelbary A, AbouGhaly M. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box–Behnken design, in-vitro evaluation and in-vivo skin deposition study. Int J Pharm. 2015;485:235–43.PubMedGoogle Scholar
  20. 20.
    Bhatia A, Singh B, Wadhwa S, Raza K, Katare OP. Novel phospholipid-based topical formulations of tamoxifen: evaluation for antipsoriatic activity using mouse-tail model. Pharm Dev Technol. 2014;19(2):160–3.PubMedGoogle Scholar
  21. 21.
    Khandavilli S, Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J Investig Dermatol. 2007;127:154–62.PubMedGoogle Scholar
  22. 22.
    Bracke S, Carretero M, Guerrero-Aspizua S, Desmet E, Illera N, Navarro M, et al. Targeted silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: development of siRNA SECosome-based novel therapies. Exp Dermatol. 2014;23:199–201.PubMedGoogle Scholar
  23. 23.
    Namdeo A, Jain N. Niosomes as drug carriers. Indian J Pharm Sci. 1996;58:41–6.Google Scholar
  24. 24.
    Abu Hashim II, Abo El-Magd NF, El-Sheakh AR, Hamed MF, Abd El-Gawad AE-GH. Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study. Int J Nanomed. 2018;13:1059–79.Google Scholar
  25. 25.
    Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm. 2007;65:259–69.PubMedGoogle Scholar
  26. 26.
    Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release. 2003;90:323–34.PubMedGoogle Scholar
  27. 27.
    Marepally S, Boakye CHA, Patel AR, Godugu C, Doddapaneni R, Desai PR, et al. Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine (London). 2014;9:2157–74.Google Scholar
  28. 28.
    Thakur A, Walia MK, Kumar SLH. Nanoemulsion in enhancement of bioavailability of poorly soluble drugs: a review. Pharmacophore. 2013;4(1):15–25.Google Scholar
  29. 29.
    Musa SH, Basri M, Fard Masoumi HR, Shamsudin N, Salim N. Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action. Int J Nanomedicine. 2017;12:2427–41.PubMedPubMedCentralGoogle Scholar
  30. 30.
    • Kaur A, Katiyar SS, Kushwah V, Jain S. Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomedicine. 2017;13:1473–82 Examined efficacy of a nanogel including both clobetasol propionate and calcipotriol highlighting the ability to combine multiple drugs in nanocarriers. The drug-loaded nanogel led to increased drug retention and anti-psoriatic efficacy compared to free drugs.PubMedGoogle Scholar
  31. 31.
    Hemmila MR, Mattar A, Taddonio MA, Arbabi S, Hamouda T, Ward PA, et al. Topical nanoemulsion therapy reduces bacterial wound infection and inflammation after burn injury. Surgery. 2010;148:499–509.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Alam MS, Ali MS, Alam N, Siddiqui MR, Shamim M, Safhi MM. In vivo study of clobetasol propionate loaded nanoemulsion for topical application in psoriasis and atopic dermatitis. Drug Invention Today. 2013;5:8–12.Google Scholar
  33. 33.
    Küchler S, Herrmann W, Panek-Minkin G, Blaschke T, Zoschke C, Kramer KD, et al. SLN for topical application in skin diseases—characterization of drug-carrier and carrier-target interactions. Int J Pharm. 2010;390:225–33.PubMedGoogle Scholar
  34. 34.
    Morganti P. Use and potential of nanotechnology in cosmetic dermatology. Clinical, cosmetic and investigational dermatology : CCID. 2010;3:5–13.PubMedGoogle Scholar
  35. 35.
    Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–77.PubMedGoogle Scholar
  36. 36.
    Fang C-L, Al-Suwayeh SA, Fang J-Y. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol. 2013;7:41–55.PubMedGoogle Scholar
  37. 37.
    Agrawal U, Gupta M, Vyas SP. Capsaicin delivery into the skin with lipidic nanoparticles for the treatment of psoriasis. Artificial Cells, Nanomedicine, And Biotechnology. 2015;43:33–9.PubMedGoogle Scholar
  38. 38.
    Raza K, Katare O, Setia A, Bhatia A, Singh B. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes. J Microencapsul. 2013;30:225–36.PubMedGoogle Scholar
  39. 39.
    Zhou X, Chen Z. Preparation and performance evaluation of emulsomes as a drug delivery system for silybin. Arch Pharm Res. 2015;38:2193–200.PubMedGoogle Scholar
  40. 40.
    Bessar H, Venditti I, Benassi L, Vaschieri C, Azzoni P, Pellacani G, et al. Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. Colloids Surf B: Biointerfaces. 2016;141:141–7.PubMedGoogle Scholar
  41. 41.
    • Nemati H, Ghahramani M-H, Faridi-Majidi R, Izadi B, Bahrami G, Madani S-H, et al. Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis. J Control Release. 2017;268:259–68 EGFR siRNA was conjugated to gold nanoparticles and efficacy was examined in an imiquimod-induced murine model. Use of the EGFR siRNA-AuNPs led to reduced T cell markers and epidermal thickness compared to nonsense siRNA-AuNPs and free EGFR siRNA, respectively. This highlights the success of siRNA treatment for psorasis, meaning that many other genes involved in psoriasis could also be targeted. PubMedGoogle Scholar
  42. 42.
    Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1–20.PubMedGoogle Scholar
  43. 43.
    Chamcheu JC, Siddiqui IA, Adhami VM, Esnault S, Bharali DJ, Babatunde AS, et al. Chitosan-based nanoformulated (−)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis. Int J Nanomedicine. 2018;13:4189–206.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Mao K-L, Fan Z-L, Yuan J-D, Chen PP, Yang JJ, Xu J, et al. Skin-penetrating polymeric nanoparticles incorporated in silk fibroin hydrogel for topical delivery of curcumin to improve its therapeutic effect on psoriasis mouse model. Colloids Surf B: Biointerfaces. 2017;160:704–14.PubMedGoogle Scholar
  45. 45.
    Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed. 2009;48:5418–29.Google Scholar
  46. 46.
    • Divya G, Panonnummal R, Gupta S, Jayakumar R, Sabitha M. Acitretin and aloe-emodin loaded chitin nanogel for the treatment of psoriasis. Eur J Pharm Biopharm. 2016;107:97–109 Created nanogels loaded with acitretin and a complementary therapy, aloe-emodin (an Aloe vera extract). Application of these two nanogels produced greater efficacy than a commercial tacrolimus cream showing that you can also apply multiple nanocarrier formulations, in addition to combining multiple drugs within a nanocarrier. PubMedGoogle Scholar
  47. 47.
    Panonnummal R, Sabitha M. Anti-psoriatic and toxicity evaluation of methotrexate loaded chitin nanogel in imiquimod induced mice model. Int J Biol Macromol. 2018;110:245–58.PubMedGoogle Scholar
  48. 48.
    • Panonnummal R, Jayakumar R, Anjaneyan G, Sabitha M. In vivo anti-psoriatic activity, biodistribution, sub-acute and sub-chronic toxicity studies of orally administered methotrexate loaded chitin nanogel in comparison with methotrexate tablet. Int J Biol Macromol. 2018;110:259–68 A lower dose of oral methotrexate included in chitin nanogels reduced psoriasis symptoms in a murine model without causing liver and lung toxicities that were seen with higher doses of methotrexate nanogels and free methotrexate. PubMedGoogle Scholar
  49. 49.
    Monteiro-Riviere NA. Skin penetration of engineered nanomaterials. In: Nasir A, Friedman A, Wang S, editors. Nanotechnology in dermatology. New York, NY: Springer New York; 2013. p. 51–61.Google Scholar
  50. 50.
    Siddique MI, Katas H, Amin MCIM, Ng S-F, Zulfakar MH, Jamil A. In-vivo dermal pharmacokinetics, efficacy, and safety of skin targeting nanoparticles for corticosteroid treatment of atopic dermatitis. Int J Pharm. 2016;507:72–82.PubMedGoogle Scholar
  51. 51.
    Wohlrab J, Goebel A, Scherer D, Bingham D, Newbert R A topical tacrolimus microemulsion for plaque-type psoriasis therapy. Drug Development & Delivery. 2012; June.Google Scholar
  52. 52.
    Chlapanidas T, Perteghella S, Leoni F, Faragò S, Marazzi M, Rossi D, et al. TNF-α blocker effect of naringenin-loaded sericin microparticles that are potentially useful in the treatment of psoriasis. Int J Mol Sci. 2014;15:13624–36.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Krueger G, Ellis CN. Psoriasis—recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53:S94–S100.PubMedGoogle Scholar
  54. 54.
    Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol. 1999;41:S7–S12.PubMedGoogle Scholar
  55. 55.
    Draelos ZD. Enhancement of topical delivery with Nanocarriers. In: Nasir A, Friedman A, Wang S, editors. Nanotechnology in dermatology. New York, NY: Springer New York; 2013. p. 87–93.Google Scholar
  56. 56.
    Cho Y, Lew B-L, Seong K, Kim N-I. An inverse relationship between ceramide synthesis and clinical severity in patients with psoriasis. J Korean Med Sci. 2004;19:859–63.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Lew B-L, Cho Y, Kim J, Sim W-Y, Kim N-I. Ceramides and cell signaling molecules in psoriatic epidermis: reduced levels of ceramides, PKC-α, and JNK. J Korean Med Sci. 2006;21:95–9.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Tokudome Y, Saito Y, Sato F, Kikuchi M, Hinokitani T, Goto K. Preparation and characterization of ceramide-based liposomes with high fusion activity and high membrane fluidity. Colloids Surf B: Biointerfaces. 2009;73:92–6.PubMedGoogle Scholar
  59. 59.
    Agarwal R, Katare O, Vyas S. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 2001;228:43–52.PubMedGoogle Scholar
  60. 60.
    Painsi C, Patscheider M, Inzinger M, Huegel R, Lange-Asschenfeldt B, Quehenberger F, et al. Psoriasis area and severity index 75 rate of classical inpatient dithranol therapy under daily life conditions. Br J Dermatol. 2015;173:815–7.PubMedGoogle Scholar
  61. 61.
    Kemény L, Ruzicka T, Braun-Falco O. Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol. 1990;3:1–20.PubMedGoogle Scholar
  62. 62.
    Assmann T, Ruzicka T. New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications. Clin Dermatol. 2002;20:505–14.PubMedGoogle Scholar
  63. 63.
    Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134:1101–2.PubMedGoogle Scholar
  64. 64.
    Pan W, Qin M, Zhang G, Long Y, Ruan W, Pan J, et al. Combination of hydrotropic nicotinamide with nanoparticles for enhancing tacrolimus percutaneous delivery. Int J Nanomedicine. 2016;Volume 11:4037–50.  https://doi.org/10.2147/IJN.S108545.CrossRefGoogle Scholar
  65. 65.
    Lui H. Phototherapy of psoriasis: update with practical pearls. J Cutan Med Surg. 2002;6:17–21.PubMedGoogle Scholar
  66. 66.
    Zanolli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol. 2003;49:78–86.Google Scholar
  67. 67.
    Stern RS. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet a therapy: a 30-year prospective study. J Am Acad Dermatol. 2012;66:553–62.PubMedGoogle Scholar
  68. 68.
    Shaikh IM, Jadhav KR, Kadam VJ. Lecithin organogels in enhancing skin delivery of drugs. In: Dragicevic N, Maibach HI, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement: drug manipulation strategies and vehicle effects. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015. p. 299–313.Google Scholar
  69. 69.
    Maza A, Montaudié H, Sbidian E, Gallini A, Aractingi S, Aubin F, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 2):19–27.PubMedGoogle Scholar
  70. 70.
    Griffiths CE. Systemic and local administration of cyclosporine in the treatment of psoriasis. J Am Acad Dermatol. 1990;23:1242–6 discussion 1246-1247.PubMedGoogle Scholar
  71. 71.
    Jeffes EW, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Liu G, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol. 1995;104:183–8.PubMedGoogle Scholar
  72. 72.
    McCullough JL, Snyder DS, Weinstein GD, Friedland A, Stein B. Factors affecting human percutaneous penetration of methotrexate and its analogues in vitro. J Investig Dermatol. 1976;66:103–7.PubMedGoogle Scholar
  73. 73.
    Stewart WD, Wallace SM, Runikis JO. Absorption and local action of methotrexate in human and mouse skin. Arch Dermatol. 1972;106:357–61.PubMedGoogle Scholar
  74. 74.
    Boyd AS, King LE. Tamoxifen-induced remission of psoriasis. J Am Acad Dermatol. 1999;41:887–9.PubMedGoogle Scholar
  75. 75.
    Ferrari VD, Jirillo A. Psoriasis and tamoxifen therapy: a case report. Tumori. 1996;82:262–3.PubMedGoogle Scholar
  76. 76.
    Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2013;8:135–55.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Boyd AS, Morris LF, Phillips CM, Menter MA. Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol. 1996;35:169–72.PubMedGoogle Scholar
  78. 78.
    Raghunath RS, Venables ZC, Millington GWM. The menstrual cycle and the skin. Clin Exp Dermatol. 2015;40:111–5.PubMedGoogle Scholar
  79. 79.
    Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol. 2011;40:66–73.PubMedGoogle Scholar
  80. 80.
    Zhao K, Singh S, Singh J. Effect of menthone on the in vitro percutaneous absorption of tamoxifen and skin reversibility. Int J Pharm. 2001;219:177–81.PubMedGoogle Scholar
  81. 81.
    Raza K, Singh B, Mahajan A, Negi P, Bhatia A, Katare OP. Design and evaluation of flexible membrane vesicles (FMVs) for enhanced topical delivery of capsaicin. J Drug Target. 2011;19:293–302.PubMedGoogle Scholar
  82. 82.
    de Jongh GJ, Zeeuwen PLJM, Kucharekova M, Pfundt R, van der Valk PG, Blokx W, et al. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol. 2005;125:1163–73.PubMedGoogle Scholar
  83. 83.
    Geusens B, Van Gele M, Braat S, De Smedt SC, Stuart MCA, Prow TW, et al. Flexible nanosomes (SECosomes) enable efficient siRNA delivery in cultured primary skin cells and in the viable epidermis of ex vivo human skin. Adv Funct Mater. 2010;20:4077–90.Google Scholar
  84. 84.
    Schneider MR, Werner S, Paus R, Wolf E. Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol. 2008;173:14–24.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Johnston A, Gudjonsson JE, Aphale A, Guzman AM, Stoll SW, Elder JT. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. J Invest Dermatol. 2011;131:329–37.PubMedGoogle Scholar
  86. 86.
    Anderson KS, Petersson S, Wong J, Shubbar E, Lokko NN, Carlström M, et al. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br J Dermatol. 2010;163:1085–9.PubMedGoogle Scholar
  87. 87.
    Flisiak I, Szterling-Jaworowska M, Baran A, Rogalska-Taranta M. Effect of psoriasis activity on epidermal growth factor (EGF) and the concentration of soluble EGF receptor in serum and plaque scales. Clin Exp Dermatol. 2014;39:461–7.PubMedGoogle Scholar
  88. 88.
    Gamret A, Price A, Fertig RM, Lev-Tov H, Nichols AJ. Complementary and alternative medicine therapies for psoriasis: a systematic review. JAMA Dermatol. 2018;154:1330–7.  https://doi.org/10.1001/jamadermatol.2018.2972.CrossRefPubMedGoogle Scholar
  89. 89.
    Balasubramanian S, Eckert RL. Keratinocyte proliferation, differentiation, and apoptosis—differential mechanisms of regulation by curcumin, EGCG and apigenin. Toxicol Appl Pharmacol. 2007;224:214–9.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Hsu S, Dickinson D, Borke J, Walsh DS, Wood J, Qin H, et al. Green tea polyphenol induces caspase 14 in epidermal keratinocytes via MAPK pathways and reduces psoriasiform lesions in the flaky skin mouse model. Exp Dermatol. 2007;16:678–84.PubMedGoogle Scholar
  91. 91.
    Krupkova O, Ferguson SJ, Wuertz-Kozak K. Stability of (−)-epigallocatechin gallate and its activity in liquid formulations and delivery systems. J Nutr Biochem. 2016;37:1–12.PubMedGoogle Scholar
  92. 92.
    Elia R, Newhide DR, Pedevillano PD, Reiss GR, Firpo MA, Hsu EW, et al. Silk–hyaluronan-based composite hydrogels: a novel, securable vehicle for drug delivery. J Biomater Appl. 2011;27:749–62.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Emily C. Murphy
    • 1
    • 2
  • Samuel W. Schaffter
    • 3
  • Adam J. Friedman
    • 1
    Email author
  1. 1.Department of DermatologyThe George Washington School of Medicine & Health SciencesWashington, DCUSA
  2. 2.School of MedicineGeorgetown UniversityWashington, DCUSA
  3. 3.Department of Chemical and Biomolecular EngineeringJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations